Download Hepatocellular Carcinoma (HCC)

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
United Kingdom
Hepatocellular Carcinoma (HCC)
The most common form of primary liver cancer in the world
More than 670,000 deaths
That is one every 47 seconds
Primary liver cancer is the SIXTH most common cancer
in the world and the SECOND leading cause of cancerrelated death.1
What causes HCC?
Hepatocellular carcinoma (HCC), which represents
about 90% of primary liver cancer, results in more than
670,000 deaths globally per annum2 – up to 1,837 people
every day or 76 people every hour.
There are around 3,700 deaths each year in the UK.2
HCC occurs mainly in
the liver of patients
affected by cirrhosis.3
In Africa and
East Asia, the most
common risk factor for
HCC (60% of cases) is
Hepatitis B virus. 5
In the developed Western
world, chronic Hepatitis C viral
infection is the major risk factor
for cirrhosis.3 Other risk factors
include Hepatitis B virus and
alcohol misuse.4
NASH (non-alcoholic
steatohepatitis) related
HCC, often caused by
obesity, is also on the
rise worldwide.
Global burden
2012
2014
2016
2018
2020
Global burden of the disease is predicted to increase.1
In the UK, the number of deaths is forecast to rise from 3,653
in 2012 to 4,189 by 2020 2 – a 15% increase.
Over the past 10 years no new first-line treatments have
become available or proven effective against HCC.6
As a result, HCC treatment lags behind other cancers.
References
1 Ferlay J et al. Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 13/March/2017.
2 Extrapolated from Ferlay J et al. Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on
13/March/2017.
3 Davis GL et al. Proc (Bayl Univ Med Cent) 2008; 21: 266–80.
4 EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–943.
5 Di Bisceglie AM. Hepatology 2009; 49 (Suppl 5): S56–60.
6 Llovet JM et al. Nat Rev Dis Primers 2016; 2: 16018. doi: 10.1038/nrdp.2016.18.
513-EUA-0317